All Stories

  1. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist

    Article • Scandinavian Journal of Urology, January 2019, Taylor & Francis

    Professor Bertrand Tombal, Francesco Boccardo, Medical Director Neal David Shore

  2. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes

    Article • Therapeutic Advances in Medical Oncology, January 2018, SAGE Publications

    Francesco Boccardo

  3. Safety of antiandrogen therapy for treating prostate cancer

    Article • Expert Opinion on Drug Safety, October 2014, Informa Healthcare

    Francesco Boccardo